Salud financiera de hoja de balance de Bavarian Nordic

Salud financiera controles de criterios 6/6

Bavarian Nordic tiene unos fondos propios totales de DKK9.3B y una deuda total de DKK17.5M, lo que sitúa su ratio deuda/fondos propios en 0.2%. Sus activos y pasivos totales son DKK13.4B y DKK4.1B respectivamente. Bavarian Nordic El EBIT de la empresa es de DKK1.5B, por lo que su ratio de cobertura de intereses es de -46.5. Su tesorería e inversiones a corto plazo ascienden a DKK1.5B.

Información clave

0.2%

Ratio deuda-patrimonio

kr.17.05m

Deuda

Ratio de cobertura de intereses	-42.8x
Efectivo	kr.1.87b
Patrimonio	kr.10.34b
Total pasivo	kr.4.01b
Activos totales	kr.14.35b

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: BVNK.FLos activos a corto plazo (DKK4.5B) de la empresa superan a sus pasivos a corto plazo (DKK2.9B).

Pasivo a largo plazo: BVNK.FLos activos a corto plazo (DKK4.5B) superan a sus pasivos a largo plazo (DKK1.2B).

Historial y análisis de deuda-patrimonio

Nivel de deuda: BVNK.F tiene más efectivo que su deuda total.

Reducción de la deuda: BVNK.F ha pasado de 28.5% a 0.2% en los últimos 5 años.

Cobertura de la deuda: BVNK.FLa deuda de la empresa está bien cubierta por el flujo de caja operativo (4288.9%).

Cobertura de intereses: BVNK.F gana más intereses de los que paga, por lo que la cobertura del pago de intereses no es preocupante.

Hoja de balance

Descubre empresas con salud financiera

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Salud financiera de hoja de balance de Bavarian Nordic

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic A/S Announces Covid-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Bavarian Nordic A/S Revises Earnings Guidance for the Full Year 2022

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate

Bavarian Nordic A/S, Annual General Meeting, Mar 30, 2023

Bavarian Nordic A/S to Report Fiscal Year 2022 Final Results on Mar 02, 2023

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2022

Bavarian Nordic A/S Receives U.S. and Eu Approvals of Its Fill and Finish Vaccine Manufacturing Facility

Bavarian Nordic A/S Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox

Bavarian Nordic A/S Raises Earnings Guidance for the Financial Guidance for 2022

Bavarian Nordic A/S Provides an Update on the Phase 3 Development of ABNCoV2, A VLP-Based, Non-Adjuvanted Covid-19 Booster Vaccine Candidate

Bavarian Nordic A/S Revises Revenue Guidance for the Year 2022

Bavarian Nordic A/S Raises Financial Guidance for the Year 2022

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic Reports Omicron Data from Phase 2 Trial of Its Covid-19 Booster Vaccine Candidate

Bavarian Nordic Announces Initiation of A Global Phase 3 Clinical Trial of Its RSV Vaccine Candidate in Older Adults

Bavarian Nordic A/S Provides Revenue Guidance for the Full Year of 2022

Bavarian Nordic A/S Reports Additional Positive Phase 2 Results for Its Covid-19 Vaccine Candidate Ahead of Phase 3 Trial

Bavarian Nordic Announces Breakthrough Therapy Designation for Its RSV Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older Adults

Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening its Capital Base

Bavarian Nordic A/S announced a financing transaction

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2021

Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine

Bavarian Nordic A/S Reports Initial Results from First-in-Human Trial of COVID-19 Vaccine

Bavarian Nordic A/S Maintains Earnings Guidance for the Full Year 2021

Bavarian Nordic A/S has completed a Follow-on Equity Offering in the amount of DKK 1.14845 billion.

Bavarian Nordic A/S Reports Encouraging Preclinical Data for COVID-19 Vaccine Candidate Ahead of First-in-Human Trial

Bavarian Nordic to Supply Smallpox Vaccines to Three European Countries

Bavarian Nordic A/S Announces Top-line Results from Phase 2 Clinical Trial of BN-Brachyury in Chordoma

Bavarian Nordic A/S Secures Second Part of Smallpox Vaccine Order from the U.S. Government

Health Canada Extends Approval of IMVAMUNE to Immunization Against Monkeypox and Orthopox Viruses

Bavarian Nordic A/S to Report Q2, 2021 Results on Aug 25, 2021

Bavarian Nordic A/S Announces Appointment of Anu Helena Kerns as Executive Vice President, People and Organization, Effective from November 2020

Bavarian Nordic A/S to Report Fiscal Year 2020 Results on Mar 12, 2021

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Descubre empresas con salud financiera